Silverarc Capital Management »

Definium Therape shares owned by Silverarc Capital Management

Quarter-by-quarter ownership of Definium Therape (DFTX) shares owned by Silverarc Capital Management from 13F filings

Historical chart of Silverarc Capital Management investment in Definium Therape

Tip: Access up to 7 years of quarterly data

All positions including Definium Therape held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Definium Therape by Silverarc Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $19M 400k 47.04

More positions owned by Silverarc Capital Management

Ascendis Pharma A/s Ord Shs (ASND)
Celcuity (CELC)
Cogent Biosciences (COGT)
Urogen Pharma (URGN)
Immunome (IMNM)
Dianthus Therapeutics (DNTH)
Rhythm Pharmaceuticals (RYTM)
Oruka Therapeutics (ORKA)
Monte Rosa Therapeutics (GLUE)
Syndax Pharmaceuticals (SNDX)
Enliven Therapeutics (ELVN)
Immunovant (IMVT)
Erasca (ERAS)
Sagimet Biosciences Com Ser A (SGMT)
Abivax Sa Sponsored Ads (ABVX)

View all positions for Silverarc Capital Management

Top funds holding Definium Therape

BlackRock
venBio Select Advisor
Driehaus Capital Management
Jupiter Topco
FMR
Geode Capital Management
Henderson Group
Capital Research and Management Company - Division 3
Octagon Capital Advisors
Wellington Management Company
Deep Track Capital
State Street Corporation
Citadel Advisors
Commodore Capital
Susquehanna International

View all funds holding Definium Therape